Back to Online Symposia Home Page
|
|
Program Description
There continue to be advances in the field of atypical antipsychotics and their application into clinical practice. Practicing clinicians need to
be educated on the most recent advances in order to provide optimal care for
their patients.
Learning Objectives
By participating in this
activity, you will be able to:
- Evaluate
the role of atypical antipsychotics, including
the effect and role of sedation, on patient outcomes in the management
of acute psychotic episodes
- Compare
and contrast the safety/tolerability profiles of atypical antipsychotics, in particular, their impact on
metabolic/endocrine disorders
- Explain
the importance of functional outcomes and quality-of-life implications,
including how and when clinicians should consider switching therapies to
improve long-term outcomes in patients with mental health disorders
Who Will Benefit
This activity was designed to meet the continuing education needs of
psychiatrists and other physicians. Other mental health
professionals may find this activity informative and should check with their
state licensing and certification boards to determine if it meets their
continuing education requirements.
Your Distinguished Faculty
John M. Kane, MD
Chairman, Department of Psychiatry, The Zucker Hillside Hospital, Glen Oaks, NY; Professor of Psychiatry, Neurology and Neuroscience, Albert Einstein College of Medicine
Faculty
Disclosures
John M. Kane, MD, serves as a consultant for Bristol-Myers Squibb Company, Eli Lilly and Company, Janssen, L.P., Pfizer Inc., Proteus, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He also serves on the Speakers Bureau for AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly and Company, and Janssen, L.P.
|
Commercial
Support
Supported by an educational grant from Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc.
Disclaimers
The content of this video
activity may include product information that is inconsistent with or outside
of the approved labeling for these products in the
United States. Before prescribing
any medication, you must familiarize yourself with the manufacturer's product
information.
To earn continuing
education credit, view this online course and complete the posttest and
evaluation provided. A passing score of 75% or more
must be achieved on the posttest. A link is provided within this online
activity to access the posttest and evaluation. You will have the option of
printing a CME Certificate for your records after submission of the
evaluation.
CME LLC, Bristol-Myers
Squibb Company and Otsuka America Pharmaceutical,
Inc. are not responsible for the speaker's statements, materials, acts or
omissions.
|
|
Continuing
Medical Education
CME LLC is accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
CME LLC designates this
educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Content Originally
Presented: March 1, 2008
Online Date: November 21, 2008
Credit Expiration Date: November 20, 2009
This activity is based on the symposium at the Psychiatric Congress
Regional Extension on March 1, 2008 in Arlington, Va. Participants who
attended the live symposium mentioned above cannot claim credit for this
activity.
|
